DICE Therapeutics, Inc.
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulat…
Biotechnology
US, South San Francisco [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -20.24 | 25.88 | 32.44 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -48.40 | 1.78 | 3.46 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Book Value | 142.81 | 10.97 | -4.52 | |
| Cash | -4.95 | 11.17 | 11.75 | |
| Capex | -803.21 | -0.04 | < 0.005 | |
| Free Cash Flow | -33.98 | -0.64 | -0.48 | |
| Revenue | 0.00 | 0.00 | 0.00 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 0.00 | 0.00 | 0.00 | |
| Operating Margin | 0.00 | 0.00 | 0.00 | |
| ROA | -84.57 | -0.06 | -0.03 | |
| ROE | -27.46 | -0.07 | 0.09 | |
| ROIC | -36.45 | -0.08 | 0.13 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of DICE is permitted for members.
5
Growth
The "Growth Entry" for the Focus of DICE is permitted for members.
6
Leverage & Liquidity